SCHEMBL14981975

SCHEMBL14981975

COC(=O)/C=C/C(=O)N(O)CCCN(C)Cc1ccc(COC(=O)Nc2cccc3ccccc23)cc1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 5/20 0.62
KDM6B O15054 2/20 0.62
KDM4C Q9H3R0 2/20 0.62
KDM4A O75164 1/20 0.62
EGLN2 Q96KS0 1/20 0.62
EGLN1 Q9GZT9 1/20 0.62
EGLN3 Q9H6Z9 1/20 0.62
HIF1AN Q9NWT6 1/20 0.62
PHF8 Q9UPP1 1/20 0.62
TRPV1 Q8NER1 5/20 0.44
ALDH1A1 P00352 4/20 0.43
HPGD P15428 1/20 0.43
PLAU P00749 1/20 0.40
ACHE P22303 1/20 0.40
LMNA P02545 1/20 0.39
MEN1 O00255 2/20 0.38
KMT2A Q03164 2/20 0.38
ABL1 P00519 1/20 0.38
RIN1 Q13671 1/20 0.38
NPC1 O15118 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14981944 0.98 KDM4E (0.64) KDM4EKDM6BKDM4CKDM4AEGLN2
SCHEMBL14981974 0.92 KDM4E (0.73) KDM4EKDM6BKDM4CKDM4AEGLN2
SCHEMBL14981958 0.90 KDM4E (0.75) KDM4EKDM6BKDM4CKDM4AEGLN2
SCHEMBL14981947 0.88 KDM4E (0.62) KDM4EKDM6BKDM4CKDM4AEGLN2
SCHEMBL14981952 0.88 KDM4E (0.62) KDM4EKDM6BKDM4CKDM4AEGLN2
SCHEMBL14985114 0.86 KDM4E (0.80) KDM4EKDM6BKDM4CKDM4AEGLN2
SCHEMBL14981957 0.86 KDM4E (0.60) KDM4EKDM6BKDM4CKDM4AEGLN2
SCHEMBL14981874 0.85 KDM4E (0.84) KDM4EKDM6BKDM4CKDM4AEGLN2
SCHEMBL14981976 0.85 KDM4E (0.60) KDM4EKDM6BKDM4CKDM4AEGLN2
SCHEMBL14981875 0.85 KDM4E (0.83) KDM4EKDM6BKDM4CKDM4AEGLN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8735622-B2 Histone demethylase inhibitors and methods for using the same THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) 2014-05-27 US disclosed
US-8735622-B2 Histone demethylase inhibitors and methods for using the same THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) 2014-05-27 US disclosed
US-20130137720-A1 HISTONE DEMETHYLASE INHIBITORS AND METHODS FOR USING THE SAME The Regents of the University of Colorado, a body corporated (US) 2013-05-30 US disclosed
US-20130137720-A1 HISTONE DEMETHYLASE INHIBITORS AND METHODS FOR USING THE SAME The Regents of the University of Colorado, a body corporated (US) 2013-05-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130137720-A1 HISTONE DEMETHYLASE INHIBITORS AND METHODS FOR USING THE SAME KDM1A, KDM3A, KDM7A KDM4E 13/4885KDM6B 15/4885KDM4C 18/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.